In the 2000's, the discovery of epidermal growth factor receptor (EGFR) mutations and a specific tyrosine kinase inhibitor (TKI) gefitinib, led to the development of personalized treatments for NSCLC (2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.